Modality
ASO
MOA
PD-1i
Target
Cl18.2
Pathway
Lipid Met
DMDRCCAML
Development Pipeline
Preclinical
~Dec 2016
→ ~Mar 2018
Phase 1
~Jun 2018
→ ~Sep 2019
Phase 2
~Dec 2019
→ ~Mar 2021
Phase 3
Jun 2021
→ Jul 2030
Phase 3Current
NCT04194690
456 pts·RCC
2024-01→2030-07·Completed
NCT06720586
1,869 pts·AML
2021-06→TBD·Completed
NCT04327429
2,122 pts·RCC
2025-06→2029-06·Active
4,447 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-06-183.2y awayPh3 Readout· RCC
2030-07-074.3y awayPh3 Readout· RCC
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Complet…
P3
Complet…
P3
Active
Catalysts
Ph3 Readout
2029-06-18 · 3.2y away
RCC
Ph3 Readout
2030-07-07 · 4.3y away
RCC
ActiveCompleted|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04194690 | Phase 3 | RCC | Completed | 456 | LiverFat |
| NCT06720586 | Phase 3 | AML | Completed | 1869 | EDSS |
| NCT04327429 | Phase 3 | RCC | Active | 2122 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Ribosacituzumab | Roche | Approved | Cl18.2 | |
| Adagrazumab | Novartis | Phase 2/3 | Cl18.2 | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| Doxafotisoran | Daiichi Sankyo | Phase 1 | Cl18.2 | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| PRA-419 | Praxis Precision | Approved | Cl18.2 |